UPDATED May 07, 2024
Companies which may present a buying opportunity after a dip in share price.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
HHR | AU$0.007 | -12.5% | -78.1% | AU$19.7m | n/a | PE6.7x | E86.3% | n/a | Energy | ||
603688 | CN¥72.37 | -7.5% | -35.4% | CN¥26.1b | CN¥114.33 | PE6x | E28.9% | 9.7% | Semiconductors | ||
301358 | CN¥37.16 | 6.1% | -8.5% | CN¥28.1b | n/a | PE19.3x | E30.3% | 1.1% | Capital Goods | ||
A036200 | ₩10,650.00 | -3.4% | 42.4% | ₩318.3b | ₩13,500.00 | PE17.5x | E38.6% | 0.8% | Semiconductors | ||
ACI | ₹629.00 | -3.6% | 15.4% | ₹77.6b | ₹743.00 | PE19.5x | E29.0% | 0.3% | Materials | ||
CAI | AU$0.13 | -10.7% | -34.2% | AU$95.2m | n/a | PB0.7x | E110.6% | n/a | Materials | ||
ZVRA | US$5.18 | 13.0% | 16.8% | US$216.6m | US$19.00 | PS7.9x | E63.6% | n/a | Pharmaceuticals & Biotech | ||
NEWBRY | kr3.05 | -10.6% | -45.1% | kr74.0m | kr8.00 | PS3.2x | E112.9% | n/a | Pharmaceuticals & Biotech | ||
RCEL | US$9.37 | 11.5% | -38.6% | US$241.7m | US$25.90 | PS4.8x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
KCB | KSh30.10 | 0.5% | -0.5% | KSh96.7b | KSh48.65 | PB0.4x | E26.0% | 0% | Banks | ||
300442 | CN¥30.25 | -3.7% | -5.3% | CN¥52.0b | CN¥36.36 | PE27.3x | E28.7% | 1.7% | Software | ||
A101390 | ₩7,440.00 | -4.9% | -27.1% | ₩67.1b | n/a | PB2.9x | E100.8% | n/a | Tech | ||
CLBIO | kr10.05 | -4.7% | -44.0% | kr216.0m | kr29.00 | PS7x | E114.8% | n/a | Pharmaceuticals & Biotech | ||
SEAPT | kr4.56 | -2.1% | -64.5% | kr1.6b | kr11.57 | PB0.9x | E54.2% | n/a | Energy | ||
FXPO | UK£0.50 | -1.9% | -54.6% | UK£293.9m | UK£1.41 | PB0.3x | E116.3% | 0% | Materials | ||
DIGN | kr1.56 | -2.5% | -60.8% | kr109.6m | kr8.60 | PS1.3x | E139.0% | n/a | Healthcare | ||
SONM | US$0.54 | 3.2% | -42.2% | US$23.5m | US$2.00 | PB1.1x | E139.9% | n/a | Tech | ||
631 | HK$6.70 | 21.6% | -37.4% | HK$21.4b | HK$10.52 | PE10.2x | E21.2% | 2.8% | Capital Goods | ||
CABP | UK£1.36 | 2.3% | n/a | UK£345.6m | UK£1.78 | PE15.1x | E34.6% | n/a | Diversified Financials | ||
OX2 | kr41.54 | 3.5% | -39.5% | kr11.3b | kr70.75 | PE12.8x | E29.9% | n/a | Capital Goods | ||
XBRANE | kr0.20 | -7.6% | -99.8% | kr305.9m | n/a | PS1.3x | E93.7% | n/a | Pharmaceuticals & Biotech | ||
FLNC | US$20.82 | 16.7% | 5.4% | US$3.7b | US$30.38 | PS1.2x | E65.2% | n/a | Capital Goods | ||
RE4 | S$0.29 | -3.3% | 0% | S$414.6m | n/a | PE4.9x | E48.4% | 6.7% | Energy | ||
BGL | AU$1.76 | -1.4% | 34.4% | AU$2.1b | AU$2.12 | PS42.2x | E34.4% | n/a | Materials |